NZ590995A - Oral formulations of salts of isophosphoramide mustard and its analogs and their use in the treatment of a condition characterised by abnormal cell growth or differentiation (such as cancer) - Google Patents
Oral formulations of salts of isophosphoramide mustard and its analogs and their use in the treatment of a condition characterised by abnormal cell growth or differentiation (such as cancer)Info
- Publication number
- NZ590995A NZ590995A NZ590995A NZ59099509A NZ590995A NZ 590995 A NZ590995 A NZ 590995A NZ 590995 A NZ590995 A NZ 590995A NZ 59099509 A NZ59099509 A NZ 59099509A NZ 590995 A NZ590995 A NZ 590995A
- Authority
- NZ
- New Zealand
- Prior art keywords
- differentiation
- cancer
- cell growth
- abnormal cell
- analogs
- Prior art date
Links
- BKCJZNIZRWYHBN-UHFFFAOYSA-N Isophosphamide mustard Chemical class ClCCNP(=O)(O)NCCCl BKCJZNIZRWYHBN-UHFFFAOYSA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000024245 cell differentiation Effects 0.000 title abstract 2
- 230000010261 cell growth Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/14—Esters of phosphoric acids containing P(=O)-halide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/14—Esters of phosphoric acids containing P(=O)-halide groups
- C07F9/1406—Esters of phosphoric acids containing P(=O)-halide groups containing the structure Hal-P(=O)-O-aryl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/20—Esters of thiophosphoric acids containing P-halide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ60113909A NZ601139A (en) | 2008-07-31 | 2009-07-30 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
NZ60380109A NZ603801A (en) | 2008-07-31 | 2009-07-30 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13753808P | 2008-07-31 | 2008-07-31 | |
PCT/US2009/052295 WO2010014841A1 (en) | 2008-07-31 | 2009-07-30 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ590995A true NZ590995A (en) | 2012-12-21 |
Family
ID=41610732
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ60113909A NZ601139A (en) | 2008-07-31 | 2009-07-30 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
NZ60380109A NZ603801A (en) | 2008-07-31 | 2009-07-30 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
NZ590995A NZ590995A (en) | 2008-07-31 | 2009-07-30 | Oral formulations of salts of isophosphoramide mustard and its analogs and their use in the treatment of a condition characterised by abnormal cell growth or differentiation (such as cancer) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ60113909A NZ601139A (en) | 2008-07-31 | 2009-07-30 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
NZ60380109A NZ603801A (en) | 2008-07-31 | 2009-07-30 | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
Country Status (16)
Country | Link |
---|---|
US (4) | US8664201B2 (es) |
EP (1) | EP2318013A4 (es) |
JP (2) | JP5711660B2 (es) |
KR (1) | KR20110038696A (es) |
CN (2) | CN102137674A (es) |
AU (1) | AU2009276512B2 (es) |
BR (1) | BRPI0916739A2 (es) |
CA (1) | CA2732290A1 (es) |
EA (1) | EA022655B1 (es) |
IL (1) | IL210921A (es) |
MX (1) | MX2011001122A (es) |
NZ (3) | NZ601139A (es) |
SG (2) | SG10201600595PA (es) |
TW (1) | TWI454266B (es) |
WO (1) | WO2010014841A1 (es) |
ZA (1) | ZA201100878B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ589418A (en) * | 2004-10-25 | 2012-03-30 | Dekk Tec Inc | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents |
US8888713B2 (en) | 2007-03-07 | 2014-11-18 | Becton, Dickinson And Company | Safety blood collection assembly with indicator |
EP3100680B1 (en) | 2007-03-07 | 2022-11-23 | Becton, Dickinson and Company | Safety blood collection assembly with indicator |
US8603009B2 (en) | 2008-03-07 | 2013-12-10 | Becton, Dickinson And Company | Flashback blood collection needle |
CA2732290A1 (en) | 2008-07-31 | 2010-02-04 | Ziopharm Oncology, Inc. | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
CN102924507A (zh) * | 2011-11-10 | 2013-02-13 | 安徽四维药业有限公司 | 一种抗肿瘤化合物及其制备方法与应用、药物组合物 |
WO2013116281A1 (en) * | 2012-01-31 | 2013-08-08 | Ziopharm Oncology, Inc. | Combination therapy including isophosphoramide mustard, analogs, or salts thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU427945A1 (ru) * | 1972-07-24 | 1974-05-15 | Институт элементоорганических соединений | СПОСОБ ПОЛУЧЕНИЯа ПОЛИФТОРАЛКИЛЗАМЕЩЕННЫХБЕНЗИЛДИХЛОРФОСФАТОВ |
ATE181551T1 (de) | 1992-04-17 | 1999-07-15 | Abbott Lab | Taxol-derivate |
US5912264A (en) | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
EP1185276B1 (en) | 1999-05-24 | 2003-12-10 | Southern Research Institute | Isophosphoramide mustard analogs and use thereof |
CO5280224A1 (es) | 2000-02-02 | 2003-05-30 | Univ Florida State Res Found | Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen |
WO2004018478A2 (en) | 2002-08-23 | 2004-03-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
NZ589418A (en) * | 2004-10-25 | 2012-03-30 | Dekk Tec Inc | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents |
EP2581367B1 (en) * | 2007-04-06 | 2015-12-30 | Ziopharm Oncology, Inc. | Salts of isophosphoramide mustard and analogs thereof |
CA2732290A1 (en) | 2008-07-31 | 2010-02-04 | Ziopharm Oncology, Inc. | Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
-
2009
- 2009-07-30 CA CA2732290A patent/CA2732290A1/en not_active Abandoned
- 2009-07-30 TW TW98125662A patent/TWI454266B/zh not_active IP Right Cessation
- 2009-07-30 EA EA201170277A patent/EA022655B1/ru not_active IP Right Cessation
- 2009-07-30 US US13/056,628 patent/US8664201B2/en not_active Expired - Fee Related
- 2009-07-30 AU AU2009276512A patent/AU2009276512B2/en not_active Ceased
- 2009-07-30 KR KR1020117004208A patent/KR20110038696A/ko not_active Application Discontinuation
- 2009-07-30 NZ NZ60113909A patent/NZ601139A/en not_active IP Right Cessation
- 2009-07-30 BR BRPI0916739A patent/BRPI0916739A2/pt not_active Application Discontinuation
- 2009-07-30 JP JP2011521338A patent/JP5711660B2/ja not_active Expired - Fee Related
- 2009-07-30 WO PCT/US2009/052295 patent/WO2010014841A1/en active Application Filing
- 2009-07-30 MX MX2011001122A patent/MX2011001122A/es active IP Right Grant
- 2009-07-30 NZ NZ60380109A patent/NZ603801A/en not_active IP Right Cessation
- 2009-07-30 SG SG10201600595PA patent/SG10201600595PA/en unknown
- 2009-07-30 SG SG2012055471A patent/SG183657A1/en unknown
- 2009-07-30 CN CN200980133758XA patent/CN102137674A/zh active Pending
- 2009-07-30 EP EP09803607.2A patent/EP2318013A4/en not_active Withdrawn
- 2009-07-30 NZ NZ590995A patent/NZ590995A/xx not_active IP Right Cessation
- 2009-07-30 CN CN201410524066.0A patent/CN104490900A/zh active Pending
-
2011
- 2011-01-27 IL IL210921A patent/IL210921A/en not_active IP Right Cessation
- 2011-02-02 ZA ZA2011/00878A patent/ZA201100878B/en unknown
-
2014
- 2014-01-29 US US14/167,169 patent/US9145431B2/en not_active Expired - Fee Related
- 2014-01-29 JP JP2014013965A patent/JP5769831B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-23 US US14/806,720 patent/US9254298B2/en not_active Expired - Fee Related
-
2016
- 2016-01-04 US US14/987,185 patent/US20160215005A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA105911C2 (uk) | Сульфонамідні похідні | |
NZ590995A (en) | Oral formulations of salts of isophosphoramide mustard and its analogs and their use in the treatment of a condition characterised by abnormal cell growth or differentiation (such as cancer) | |
MX2010008921A (es) | Derivados de oxazolidinona. | |
UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
IN2012DN01233A (es) | ||
MX2009011816A (es) | Derivados de piridina. | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
MX2011011136A (es) | Eteres diarilicos. | |
TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
MX2011012122A (es) | Derivados de tiofeno. | |
NZ601483A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
MY176944A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
MY155570A (en) | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 | |
MX2010009163A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211. | |
MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
MX2010006241A (es) | Derivados de aminotriazol como agonistas de alx. | |
TW200616985A (en) | Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use | |
GB0722077D0 (en) | Compounds | |
MX2010008460A (es) | Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular. | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
UA99787C2 (en) | Lactams as beta secretase inhibitors | |
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
MX2012006026A (es) | Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JUL 2016 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20130504 |
|
LAPS | Patent lapsed |